Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 6;23(21):13604.
doi: 10.3390/ijms232113604.

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Mariarosaria Saponaro  1 , Luigi Annunziata  1 , Antonella Turla  2 , Ilaria Viganò  3 , Michele De Laurentiis  4 , Mario Giuliano  1   5 , Lucia Del Mastro  6 , Filippo Montemurro  7 , Fabio Puglisi  8   9 , Carmine De Angelis  1   5 , Giuseppe Buono  4 , Francesco Schettini  10   11 , Grazia Arpino  1   5
Affiliations
Review

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Mariarosaria Saponaro et al. Int J Mol Sci. .

Abstract

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.

Keywords: clinical score; extended endocrine therapy; genomic assays; hormone receptor-positive breast cancer; late recurrence.

PubMed Disclaimer

Conflict of interest statement

M.S., L.A. and A.T. declare no conflict of interest. I.V. declared participation on advisory boards for Novartis, activities as a speaker for Istituto Gentili, manuscript writing for Roche. F.M. has received consultancy fees from Roche, Novartis, Astra Zeneca, Eli Lilly, Pfizer, SeaGen, Pierre Fabre and Daiichi Sankyo and has received travel grants from Roche and Astra Zeneca. F.S. declared personal fees from Novartis for educational activities. F.P. declare Honoraria for advisory boards, activities as a speaker, travel grants, research grants for Amgen, Astrazeneca, Daichii Sankyo, Celgene, Eisai, Eli Lilly, Gilead, Ipsen, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda, Viatris; research funding for Astrazeneca, Eisai, Roche. M.D.L. declare Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Astrazeneca, Amgen, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, Exact Science, Gilead, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen; Support for attending meetings and/or travel for Astrazeneca; Participation on a Data Safety Monitoring Board or Advisory Board for (adv board) Astrazeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen. L.D.M. declared grants from Eli Lilly, during the conduct of the study; personal fees from Eli Lilly, MSD, Genomic Health, Pierre Fabre, Daiichi Sankyo, Astrazeneca, Seagen, Novartis, Ipsen and Gilead, personal fees and non- financial support from Roche, Pfizer and Eisai, outside the submitted work. G.B. declare Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Novartis, GSK, Eli-Lilly, Astrazeneca, Roche, Daiichi Sankyo, Exact Science, Genetic; Support for attending meetings and/or travel for Roche.

References

    1. Waks G.A., Winer E.P. Breast cancer treatment: A review. JAMA. 2019;321:288–300. doi: 10.1001/jama.2018.19323. - DOI - PubMed
    1. Schettini F., Giuliano M., Giudici F., Conte B., De Placido P., Venturini S., Rognoni C., Di Leo A., Locci M., Jerusalem G., et al. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers. 2021;13:1458. doi: 10.3390/cancers13061458. - DOI - PMC - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomized trials. Lancet. 2015;386:1341–1352. doi: 10.1016/S0140-6736(15)61074-1. - DOI - PubMed
    1. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patients-level meta-analysis of randomized trials. Lancet. 2011;378:711–784. - PMC - PubMed
    1. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., Tobias J.S., et al. Results of the ATAC (Arimidex, Tamoxifen; Alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62. - PubMed

MeSH terms